(ACT) AlzChem - Ratings and Ratios
Nitriles, Silicon, Carbon, Ceramics
ACT EPS (Earnings per Share)
ACT Revenue
Description: ACT AlzChem
AlzChem Group AG, listed on XETRA under the ticker symbol ACT, is a German specialty chemicals company. The firms financial performance is reflected in its yearly Income Tax Expense, a critical component in understanding its profitability.
With a market capitalization of approximately €1.6 billion, AlzChem operates within the specialty chemicals sub-industry, a sector known for its niche products and high-margin potential. The companys return on equity (RoE) stands at 28.25%, indicating a strong ability to generate profits from shareholder equity.
Key economic drivers for AlzChem include demand for its specialty chemicals products, global economic trends, and the competitive landscape within its sub-industry. The companys price-to-earnings (P/E) ratio is 28.43, with a forward P/E of 26.04, suggesting that investors have certain expectations regarding its future earnings growth.
To further evaluate AlzChems performance, one could examine additional KPIs such as revenue growth, EBITDA margins, and debt-to-equity ratio. These metrics provide insights into the companys operational efficiency, financial health, and capacity for future investments. A beta of 0.804 indicates that AlzChems stock price tends to be less volatile than the overall market, potentially making it a more stable investment option for risk-averse investors.
Analyzing AlzChems stock performance, the current price is €147.60, with moving averages (SMA20, SMA50, SMA200) providing insights into its short-term and long-term trends. The average trading volume is around 25,113 shares, indicating a reasonable level of liquidity.
ACT Stock Overview
| Market Cap in USD | 1,812m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
ACT Stock Ratings
| Growth Rating | 92.2% |
| Fundamental | 78.9% |
| Dividend Rating | 71.2% |
| Return 12m vs S&P 500 | 155% |
| Analyst Rating | - |
ACT Dividends
| Dividend Yield 12m | 1.63% |
| Yield on Cost 5y | 8.53% |
| Annual Growth 5y | 9.86% |
| Payout Consistency | 94.6% |
| Payout Ratio | 120.8% |
ACT Growth Ratios
| Growth Correlation 3m | 68.8% |
| Growth Correlation 12m | 98.5% |
| Growth Correlation 5y | 63.3% |
| CAGR 5y | 47.19% |
| CAGR/Max DD 5y | 1.20 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | 211.40 |
| Beta | 0.140 |
| Volatility | 52.48% |
| Current Volume | 22.3k |
| Average Volume 20d | 20k |
| Stop Loss | 141.9 (-4.5%) |
| Signal | 2.08 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (57.9m TTM) > 0 and > 6% of Revenue (6% = 33.2m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -14.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 34.96% (prev 26.43%; Δ 8.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 112.6m > Net Income 57.9m (YES >=105%, WARN >=100%) |
| Net Debt (-8.72m) to EBITDA (75.0m) ratio: -0.12 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (10.1m) change vs 12m ago -0.72% (target <= -2.0% for YES) |
| Gross Margin 63.10% (prev 37.26%; Δ 25.83pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 109.0% (prev 119.2%; Δ -10.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.50 (EBITDA TTM 75.0m / Interest Expense TTM 5.52m) >= 6 (WARN >= 3) |
Altman Z'' 4.86
| (A) 0.35 = (Total Current Assets 298.8m - Total Current Liabilities 105.2m) / Total Assets 553.0m |
| (B) 0.36 = Retained Earnings (Balance) 199.1m / Total Assets 553.0m |
| (C) 0.11 = EBIT TTM 58.0m / Avg Total Assets 508.2m |
| (D) 0.60 = Book Value of Equity 199.1m / Total Liabilities 333.6m |
| Total Rating: 4.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.87
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 2.75% = 1.38 |
| 3. FCF Margin 7.60% = 1.90 |
| 4. Debt/Equity 0.20 = 2.48 |
| 5. Debt/Ebitda 0.59 = 2.24 |
| 6. ROIC - WACC 11.27% = 12.50 |
| 7. RoE 27.70% = 2.31 |
| 8. Rev. Trend 17.57% = 0.88 |
| 9. Rev. CAGR 0.95% = 0.12 |
| 10. EPS Trend 75.66% = 1.89 |
| 11. EPS CAGR 16.78% = 1.68 |
What is the price of ACT shares?
Over the past week, the price has changed by +4.21%, over one month by -1.07%, over three months by +22.81% and over the past year by +196.67%.
Is AlzChem a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACT is around 183.82 EUR . This means that ACT is currently undervalued and has a potential upside of +23.7% (Margin of Safety).
Is ACT a buy, sell or hold?
What are the forecasts/targets for the ACT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 143.6 | -3.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 201.1 | 35.3% |
ACT Fundamental Data Overview
Market Cap EUR = 1.55b (1.55b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 64.3m EUR (Cash only, last quarter)
P/E Trailing = 26.0245
P/E Forward = 24.7525
P/S = 2.7336
P/B = 6.9135
Beta = 0.804
Revenue TTM = 553.7m EUR
EBIT TTM = 58.0m EUR
EBITDA TTM = 75.0m EUR
Long Term Debt = 37.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 6.36m EUR (from shortLongTermDebt, last quarter)
Debt = 44.3m EUR (Calculated: Short Term 6.36m + Long Term 37.9m)
Net Debt = -8.72m EUR (from netDebt column, last fiscal year)
Enterprise Value = 1.53b EUR (1.55b + Debt 44.3m - CCE 64.3m)
Interest Coverage Ratio = 10.50 (Ebit TTM 58.0m / Interest Expense TTM 5.52m)
FCF Yield = 2.75% (FCF TTM 42.1m / Enterprise Value 1.53b)
FCF Margin = 7.60% (FCF TTM 42.1m / Revenue TTM 553.7m)
Net Margin = 10.46% (Net Income TTM 57.9m / Revenue TTM 553.7m)
Gross Margin = 63.10% ((Revenue TTM 553.7m - Cost of Revenue TTM 204.3m) / Revenue TTM)
Tobins Q-Ratio = 7.67 (Enterprise Value 1.53b / Book Value Of Equity 199.1m)
Interest Expense / Debt = 2.90% (Interest Expense 1.28m / Debt 44.3m)
Taxrate = 28.00% (from yearly Income Tax Expense: 21.1m / 75.3m)
NOPAT = 41.7m (EBIT 58.0m * (1 - 28.00%))
Current Ratio = 2.84 (Total Current Assets 298.8m / Total Current Liabilities 105.2m)
Debt / Equity = 0.20 (Debt 44.3m / last Quarter total Stockholder Equity 217.3m)
Debt / EBITDA = 0.59 (Net Debt -8.72m / EBITDA 75.0m)
Debt / FCF = 1.05 (Debt 44.3m / FCF TTM 42.1m)
Total Stockholder Equity = 209.1m (last 4 quarters mean)
RoA = 10.48% (Net Income 57.9m, Total Assets 553.0m )
RoE = 27.70% (Net Income TTM 57.9m / Total Stockholder Equity 209.1m)
RoCE = 23.47% (Ebit 58.0m / (Equity 209.1m + L.T.Debt 37.9m))
RoIC = 17.68% (NOPAT 41.7m / Invested Capital 236.1m)
WACC = 6.41% (E(1.55b)/V(1.59b) * Re(6.53%)) + (D(44.3m)/V(1.59b) * Rd(2.90%) * (1-Tc(0.28)))
Shares Correlation 5-Years: -89.40 | Cagr: -0.16%
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈66.7m ; Y1≈43.8m ; Y5≈20.0m
Fair Price DCF = 38.79 (DCF Value 393.8m / Shares Outstanding 10.2m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 17.57 | Revenue CAGR: 0.95%
Rev Growth-of-Growth: 2.55
EPS Correlation: 75.66 | EPS CAGR: 16.78%
EPS Growth-of-Growth: -7.13